Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) to Post Q1 2024 Earnings of ($0.32) Per Share, Leerink Partnrs Forecasts

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a note issued to investors on Monday, January 29th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($0.32) for the quarter. The consensus […]

Related Keywords

Canada ,China ,United States ,Raymond James ,William Blair ,Leerink Partnrs ,Nasdaq ,Millennium Management ,China Universal Asset Management Co ,Royal Bank ,Fusion Pharmaceuticals Trading ,Citadel Advisors ,Fusion Pharmaceuticals ,Fusion Pharmaceuticals Inc ,Renaissance Technologies ,Schonfeld Strategic Advisors ,News Ratings For Fusion Pharmaceuticals Daily ,Institutional Investors Weigh In On Fusion Pharmaceuticals ,Fusion Pharmaceuticals Company Profile ,Free Report ,Fusion Pharmaceutical ,Get Free Report ,Strategic Advisors ,Universal Asset Management ,Pharmaceuticals Inc ,Fusion Pharmaceuticals Daily ,Nasdaq Fusn ,Fusn ,Medical ,Earnings Estimates ,